Description: ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Home Page: www.obseva.com
Chemin des Aulx, 12
Geneva,
1228
Switzerland
Phone:
41 22 552 38 40
Officers
| Name | Title |
|---|---|
| Mr. Brian O'Callaghan | CEO & Director |
| Dr. Ernest Loumaye M.D., OB/GYN, Ph.D. | Co-Founder & Director |
| Mr. Fabien Lefebvre de Ladonchamps | Chief Admin. Officer |
| Mr. Clive Bertram | Chief Commercial Officer |
| Mr. Luigi Marro | Chief Transformation Officer |
| Mr. William Michael Brown | Chief Financial Officer |
| Ms. Delphine Renaud | Personal Assistant to the CSO and Head of R&D |
| Ms. Katja Buhrer | Chief Strategy Officer |
| Ms. Brandi Howard Ph.D. | Chief Clinical Officer |
Exchange: SW
Country: CH : Switzerland
Currency: Swiss Franc (CHF)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.727 |
| Price-to-Sales TTM: | 3.8338 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 48 |